Yoshihiro Tadori
Otsuka (Japan)(JP)Otsuka Pharmaceutical (Spain)(ES)
Publications by Year
Research Areas
Neurotransmitter Receptor Influence on Behavior, Receptor Mechanisms and Signaling, Schizophrenia research and treatment, Treatment of Major Depression, Neuroscience and Neuropharmacology Research
Most-Cited Works
- → Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study(2016)105 cited
- → Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic(2005)85 cited
- → Differences in agonist/antagonist properties at human dopamine D2 receptors between aripiprazole, bifeprunox and SDZ 208-912(2007)69 cited
- → Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors(2008)66 cited
- → Functional potencies of dopamine agonists and antagonists at human dopamine D2 and D3 receptors(2011)63 cited
- → Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6‐week, randomized, double‐blind, placebo‐controlled study(2018)61 cited
- → In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors(2011)55 cited
- → Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors(2009)38 cited
- → Pharmacokinetics and Safety of Brexpiprazole Following Multiple‐Dose Administration to Japanese Patients With Schizophrenia(2017)37 cited
- → Long‐term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52‐week, open‐label study(2018)35 cited